Search Results 1031-1040 of 17146 for monoclonal antibody

  1. Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors - Mayo Clinic

    Monoclonal antibodies =< 3 half-lives prior to registration; Radiation therapy. Last fraction of craniospinal irradiation or total body irradiation =< 3 ...

  2. At-Home Self-Collection for Pre-Transplant Patients - Mayo Clinic

    The objectives of this study are to determine whether adequate blood volumes can be obtained with the Tasso+ device for anti-HLA antibody testing, to ...

  3. Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Serum monoclonal protein ≥ 1.0 g/dL; > 200 mg of monoclonal protein in the urine on 24 hour electrophoresis; Serum immunoglobulin free light chain ≥ 10 mg ...

  4. PRE-I-SPY Phase I/Ib Oncology Platform Program - Mayo Clinic

    small molecules and >30 mL/min for monoclonal antibodies unless otherwise specified in the Arm Specific Eligibility. These cut-off values may be modified ...

  5. Immune globulin-slra (intravenous route) - Side effects & uses - Mayo Clinic

    Description. Immune globulin-slra injection contains antibodies that make your immune system stronger. It is used for patients who have primary humoral ...

  6. Study of Oraxol and Pembrolizumab in Subjects with Advanced Solid Tumors - Mayo Clinic

    - Chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies (but excluding nitrosurea, mitomycin-C, targeted therapy, and radiation) ≤ 28 ...

  7. Medical Research & Education - Mayo Clinic News Network

    Mayo Clinic launches neutralizing antibody test to advance COVID-19 therapies featured image. Individualized Medicine. Mayo Clinic launches neutralizing ...

  8. A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS - Mayo Clinic

    Previous Treatment with a B-cell depleting antibody; History of severe allergic reactions to humanized or murine monoclonal antibodies; Treatment with any ...

  9. A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion - Mayo Clinic

    (dFLC) >= 50 mg/L. - Has previously been exposed to a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody. Exclusion Criteria: - Known history of ...

  10. A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma - Mayo Clinic

    Must have relapsed after or failed to respond to at least 2 prior lines of treatment, including one anti-CD20 monoclonal antibody (mAb) and a Bruton's tyrosine ...